Current anti-PD1/PDL1 therapies block the interaction between PD1 and PDL1, effectively reactivating suppressed immune cells and initiating an anti-tumor immune response [13,41,42,43,44,45,46,47,48,49,50,51,52]. The gene discussed is PDCD1; the disease is neoplasm.